Literature DB >> 12818418

Autoantibodies against modified low-density lipoproteins in coronary artery disease.

Per Tornvall1, Georg Waeg, Jan Nilsson, Anders Hamsten, Jan Regnström.   

Abstract

OBJECTIVES: To evaluate the importance of different autoantibodies against modified low-density lipoprotein (LDL) in patients with coronary artery disease (CAD).
BACKGROUND: Previous studies of autoantibodies against LDL have shown that patients with CAD have increased titers of autoantibodies against LDL modified by copper and malondialdehyde (MDA), whereas there is a lack of information about autoantibody titers against LDL modified by hypochlorite (HOCl). Studies of autoantibodies in relation to severity of atherosclerosis are few and have reached divergent results. Furthermore, no data exist on the relationship between autoantibody titers and prognosis.
METHODS: Titers of autoantibodies against copper-, MDA- and HOCl-modified LDL were determined in serum by ELISA. Autoantibody titers in young male survivors of a first myocardial infarction were compared with those of healthy controls and related to coronary angiographic findings and to prognosis during 11 years of follow-up.
RESULTS: Patients had higher titers of autoantibodies against LDL modified by copper and MDA than controls. In contrast, no consistent associations were found between autoantibody titers and global severity of coronary atherosclerosis or number and severity of coronary stenoses and prognosis.
CONCLUSIONS: The prognostic value of autoantibodies against modified LDL is limited in young postinfarction patients despite the fact that autoantibody titers against copper- and MDA-modified LDL are raised compared with healthy controls. Furthermore, the results indicate that autoantibodies against modified LDL are not protective in later stages of coronary atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12818418     DOI: 10.1016/s0021-9150(03)00021-2

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  Relation between plasma oxLDL antibodies and oxLDL in the circulation.

Authors:  Yan Wang; Xueqiang Fang; Shumei Wang; Yueqiu Feng; Jinghai Yin
Journal:  Inflammation       Date:  2006-12-02       Impact factor: 4.092

Review 2.  The immune system in atherosclerosis.

Authors:  Göran K Hansson; Andreas Hermansson
Journal:  Nat Immunol       Date:  2011-03       Impact factor: 25.606

3.  Association of anti-oxidized LDL and candidate genes with severity of coronary stenosis in the Women's Ischemia Syndrome Evaluation study.

Authors:  Qi Chen; Steven E Reis; Candace Kammerer; Wendy Craig; Dennis M McNamara; Richard Holubkov; Barry L Sharaf; George Sopko; Daniel F Pauly; C Noel Bairey Merz; M Ilyas Kamboh
Journal:  J Lipid Res       Date:  2011-01-20       Impact factor: 5.922

4.  Effects of grape pomace on the antioxidant defense system in diet-induced hypercholesterolemic rabbits.

Authors:  Chang-Sook Choi; Hae-Kyung Chung; Mi-Kyung Choi; Myung-Hwa Kang
Journal:  Nutr Res Pract       Date:  2010-04-28       Impact factor: 1.926

5.  Serum Malondialdehyde-Modified Low-Density Lipoprotein Is a Risk Factor for Central Arterial Stiffness in Maintenance Hemodialysis Patients.

Authors:  Jia-Sian Hou; Chih-Hsien Wang; Yu-Hsien Lai; Chiu-Huang Kuo; Yu-Li Lin; Bang-Gee Hsu; Jen-Pi Tsai
Journal:  Nutrients       Date:  2020-07-21       Impact factor: 5.717

6.  Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes.

Authors:  G N Fredrikson; D V Anand; D Hopkins; R Corder; R Alm; E Bengtsson; P K Shah; A Lahiri; J Nilsson
Journal:  Diabetologia       Date:  2009-05-12       Impact factor: 10.122

7.  Circulating autoantibodies against the apolipoprotein B-100 peptides p45 and p210 in relation to the occurrence of carotid plaques in 64-year-old women.

Authors:  Björn Fagerberg; Ulrica Prahl Gullberg; Ragnar Alm; Jan Nilsson; Gunilla Nordin Fredrikson
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.